Cardiovascular Outcomes

Effect of SGLT2 Inhibitors on the Incidence of Right Ventricular Dysfunction in Patients with Chronic Heart Failure

by Prateek Chopra | May 30, 2026 | Cardiology Conferences | ESC-HF 2026 Right ventricular dysfunction (RVD) is a major complication of left ventricular heart failure (LVHF), and although neurohormonal modulation improves prognosis in LVHF, its impact on reducing RVD incidence remains limited. Data regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and RVD incidence are currently lacking. This study […]

Effect of SGLT2 Inhibitors on the Incidence of Right Ventricular Dysfunction in Patients with Chronic Heart Failure Read Post »

Leave a Comment / ESC-HF Day 4 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiovascular Outcomes, Heart Failure with Reduced Ejection Fraction (HFrEF), Right Ventricular Dysfunction (RVD), SGLT2 Inhibitors

Effect of Different Treatment Durations of Sodium–Glucose Cotransporter2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes:A Target Trial Emulation Study

by Prateek Chopra | July 4, 2026 | Diabetes Conferences | ADA 2026 Clinical Background Methods Study Population Key Findings Clinical Implications In this large nationwide analysis, longer SGLT2i treatment duration was associated with progressively greater reductions in major adverse cardiovascular events and hospitalization for heart failure, supporting sustained therapy to optimize cardiovascular outcomes in patients with type 2 diabetes.

Effect of Different Treatment Durations of Sodium–Glucose Cotransporter2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes:A Target Trial Emulation Study Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Outcomes, Heart Failure Hospitalization, Major Adverse Cardiovascular Events (MACE), SGLT2 Inhibitors, Type 2 Diabetes (T2DM)

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 Clinical Context Methods Study Population Cardiovascular Outcomes in the Trial-Matched Cohort Cardiovascular Outcomes in the Non-Trial Cohort Clinical Implications GLP-1RA therapy was associated with a lower risk of major adverse cardiovascular events among individuals meeting LEADER trial eligibility criteria but not among those outside the trial population.

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 28, 2026 / ADA 2026, Cardiovascular Outcomes, GLP-1 Receptor Agonists, LEADER Trial, Real-World Evidence, Type 2 Diabetes, Type 2 Diabetes (T2DM)